Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhao-Ru Dong

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Immunotherapy|May 4, 2023
Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysisHui Liu, Chun-Cheng Yang, Yun-Long Ma, et al.
Metabolism: Clinical and Experimental|May 25, 2025
Targeting SAMD1 enhances the effect of anti-PD-1 plus lenvatinib therapy in hepatocellular carcinoma by increasing ferroptosis sensitivity and immune responseGuo-Qiang Pan, Yu-Chuan Yan, Rui-Zhe Li, et al.
Expert Review of Gastroenterology & Hepatology|May 6, 2023
Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysisHui Liu, Cheng-Long Han, Bao-Wen Tian, et al.
Food & Function|April 22, 2025
An umbrella review of the association between dietary factors and hepatocellular carcinoma riskHan Li, Qi-Hang Cao, Hui Liu, et al.
Cancer Immunology, Immunotherapy : CII|February 22, 2023
Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patientsCheng-Long Han, Bao-Wen Tian, Lun-Jie Yan, et al.
The Oncologist|June 28, 2024
Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysisShi-Jia Liu, Lun-Jie Yan, Han-Chao Wang, et al.
Clinical & Experimental Metastasis|June 12, 2023
Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysisBao-Wen Tian, Cheng-Long Han, Han-Chao Wang, et al.
JHEP Reports : Innovation in Hepatology|October 20, 2025
A pathomics-integrated multimodal model to evaluate chemoimmunotherapy efficacy in unresectable intrahepatic cholangiocarcinomaQi-Hang Cao, Han Li, Peng-Fei Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2018
COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib TreatmentXiao-Feng Dong, Tian-Qi Liu, Xu-Ting Zhi, et al.
Journal of Gastroenterology and Hepatology|April 30, 2024
Role of hepatitis B core-related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta-analysisQi-Hang Cao, Hui Liu, Lun-Jie Yan, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Immunotherapy|May 4, 2023
Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysisHui Liu, Chun-Cheng Yang, Yun-Long Ma, et al.
Metabolism: Clinical and Experimental|May 25, 2025
Targeting SAMD1 enhances the effect of anti-PD-1 plus lenvatinib therapy in hepatocellular carcinoma by increasing ferroptosis sensitivity and immune responseGuo-Qiang Pan, Yu-Chuan Yan, Rui-Zhe Li, et al.
Expert Review of Gastroenterology & Hepatology|May 6, 2023
Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysisHui Liu, Cheng-Long Han, Bao-Wen Tian, et al.
Food & Function|April 22, 2025
An umbrella review of the association between dietary factors and hepatocellular carcinoma riskHan Li, Qi-Hang Cao, Hui Liu, et al.
Cancer Immunology, Immunotherapy : CII|February 22, 2023
Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patientsCheng-Long Han, Bao-Wen Tian, Lun-Jie Yan, et al.
The Oncologist|June 28, 2024
Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysisShi-Jia Liu, Lun-Jie Yan, Han-Chao Wang, et al.
Clinical & Experimental Metastasis|June 12, 2023
Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysisBao-Wen Tian, Cheng-Long Han, Han-Chao Wang, et al.
JHEP Reports : Innovation in Hepatology|October 20, 2025
A pathomics-integrated multimodal model to evaluate chemoimmunotherapy efficacy in unresectable intrahepatic cholangiocarcinomaQi-Hang Cao, Han Li, Peng-Fei Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2018
COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib TreatmentXiao-Feng Dong, Tian-Qi Liu, Xu-Ting Zhi, et al.
Journal of Gastroenterology and Hepatology|April 30, 2024
Role of hepatitis B core-related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta-analysisQi-Hang Cao, Hui Liu, Lun-Jie Yan, et al.
Pageof 8